showed that EIF4A3-mediated circPRKCI facilitated cancer progression by modulating WBP2 and activating the AKT signaling pathway, suggesting a potential novel therapeutic strategy for triple-negative breast cancer (45). Here, EIF4A3 is linked to triple-negative breast carcinoma.